用于治疗非小细胞肺癌的联合检查点抑制剂：双重抗CTLA-4和抗PD-1/PD-L1疗法的最新进展
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
作者信息
Puri Sonam, Shafique Michael
机构信息
Division of Medical Oncology, Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, USA.
Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
出版信息
Drugs Context. 2020 Jan 13;9. doi: 10.7573/dic.2019-9-2. eCollection 2020.
Abstract
Immunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of the treatment armamentarium in NSCLC. This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade. Despite the challenges, this paper also presents some solutions and ways to improve our understanding and implementation of such combinations in the future.
摘要
免疫疗法彻底改变了癌症治疗方式。在非小细胞肺癌（NSCLC）中，免疫检查点抑制剂单药治疗已改善了转移性疾病患者的生存率。免疫检查点抑制剂联合治疗在临床前模型中已显示出协同作用，目前正在作为NSCLC治疗手段的一部分进行研究。本综述讨论了联合免疫检查点阻断的基本原理、疗效及挑战。尽管存在挑战，但本文也提出了一些解决方案以及未来增进对此类联合治疗的理解与应用的方法。
相似文献
1
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.用于治疗非小细胞肺癌的联合检查点抑制剂：双重抗CTLA-4和抗PD-1/PD-L1疗法的最新进展
Drugs Context. 2020 Jan 13;9. doi: 10.7573/dic.2019-9-2. eCollection 2020.
2
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
3
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
4
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade.对双重PD-1/CTLA-4阻断敏感的PD-L1阴性晚期非小细胞肺癌的临床意义及分子注释
Immunotargets Ther. 2024 Sep 6;13:435-445. doi: 10.2147/ITT.S476040. eCollection 2024.
5
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
6
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).表皮生长因子受体（EGFR）通路、Yes 相关蛋白（YAP）与非小细胞肺癌（NSCLC）中程序性死亡配体 1（PD-L1）的调控。
Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821.
7
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?单独使用PD-1检查点阻断疗法或联合使用PD-1和CTLA-4阻断疗法作为肺癌的免疫疗法？
Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18.
8
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.PD-1 或 PD-L1 抑制剂联合治疗癌症。
Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23.
9
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.双重 CTLA-4 和 PD-L1 阻断抑制结直肠癌高度侵袭性原位模型中的肿瘤生长和肝转移。
Neoplasia. 2019 Sep;21(9):932-944. doi: 10.1016/j.neo.2019.07.006. Epub 2019 Aug 11.
10
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
引用本文的文献
1
The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer.非小细胞肺癌肿瘤微环境特异性疗法的现状
Cancers (Basel). 2025 May 22;17(11):1732. doi: 10.3390/cancers17111732.
2
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors.接受免疫检查点抑制剂治疗患者的不良心血管事件及心脏影像学表现
PLoS One. 2024 Dec 2;19(12):e0314555. doi: 10.1371/journal.pone.0314555. eCollection 2024.
3
Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies.肺癌炎性肿瘤微环境中的旁分泌调节与免疫系统通路：对肿瘤发生及免疫治疗策略的见解
Cancers (Basel). 2024 Mar 10;16(6):1113. doi: 10.3390/cancers16061113.
4
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.p53 缺失和突变异质性驱动高肿瘤突变负荷的自发小鼠肺癌模型中的免疫抵抗。
Cancer Cell. 2023 Oct 9;41(10):1731-1748.e8. doi: 10.1016/j.ccell.2023.09.006. Epub 2023 Sep 28.
5
Hot and cold tumors: Immunological features and the therapeutic strategies.冷热肿瘤：免疫特征与治疗策略
MedComm (2020). 2023 Aug 26;4(5):e343. doi: 10.1002/mco2.343. eCollection 2023 Oct.
6
Skin Infiltrate Composition as a Telling Measure of Responses to Checkpoint Inhibitors.皮肤浸润成分作为检查点抑制剂反应的一种有效衡量指标
JID Innov. 2023 Feb 9;3(5):100190. doi: 10.1016/j.xjidi.2023.100190. eCollection 2023 Sep.
7
Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors.修订肺癌细胞因子诱导的杀伤细胞治疗领域：聚焦免疫检查点抑制剂。
Int J Mol Sci. 2023 Mar 15;24(6):5626. doi: 10.3390/ijms24065626.
8
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.转移性非小细胞肺癌的免疫治疗：治疗进展和生物标志物。
Curr Oncol. 2023 Feb 16;30(2):2366-2387. doi: 10.3390/curroncol30020181.
9
Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model.靶向 EGFR 联合营养补充剂对肺癌小鼠模型抗肿瘤疗效的影响。
Mar Drugs. 2022 Nov 29;20(12):751. doi: 10.3390/md20120751.
10
Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors.基于模型的替雷利珠单抗在晚期肿瘤患者中的群体药代动力学分析。
CPT Pharmacometrics Syst Pharmacol. 2023 Jan;12(1):95-109. doi: 10.1002/psp4.12880. Epub 2022 Nov 23.
本文引用的文献
1
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
2
Nivolumab plus ipilimumab in non-small-cell lung cancer.纳武利尤单抗联合伊匹单抗用于非小细胞肺癌。
Future Oncol. 2019 Jul;15(19):2287-2302. doi: 10.2217/fon-2019-0031. Epub 2019 May 8.
3
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.免疫检查点抑制剂的临床药代动力学和药效学。
Clin Pharmacokinet. 2019 Jul;58(7):835-857. doi: 10.1007/s40262-019-00748-2.
4
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.纳武利尤单抗联合伊匹单抗一线治疗晚期非小细胞肺癌（CheckMate 568）：程序性死亡配体 1 和肿瘤突变负荷作为生物标志物的结果。
J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
5
Tumor Mutation Burden: Is It Ready for the Clinic?肿瘤突变负荷：它准备好应用于临床了吗？
J Clin Oncol. 2018 Oct 20;36(30):2978-2979. doi: 10.1200/JCO.2018.79.3398. Epub 2018 Sep 4.
6
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).双抗 CTLA4 和 PD-1/PD-L1 阻断免疫疗法在癌症中的现状和未来；黑色素瘤和非小细胞肺癌 (NSCLC) 临床试验的经验教训。
J Immunother Cancer. 2018 May 16;6(1):39. doi: 10.1186/s40425-018-0349-3.
7
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
8
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
9
New insights into the structure of the MHC class I peptide-loading complex and mechanisms of TAP inhibition by viral immune evasion proteins.新视角下 MHC I 类肽加载复合物的结构和病毒免疫逃逸蛋白对 TAP 抑制的机制。
Mol Immunol. 2019 Sep;113:103-114. doi: 10.1016/j.molimm.2018.03.020. Epub 2018 Mar 30.
10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.接受免疫检查点抑制剂治疗患者免疫相关不良事件的管理：美国临床肿瘤学会临床实践指南摘要
J Oncol Pract. 2018 Apr;14(4):247-249. doi: 10.1200/JOP.18.00005. Epub 2018 Mar 8.
Zotero 插件